AKN-028

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameAKN-028
Drug Alias NameBVT-IIAKN-028BVT-63628
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionStem cell growth factor receptor inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsStem cell growth factor receptorTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaSwedenPoland +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAkinion
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAkinion Pharmaceuticals Ab
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A